References
- Watt DC, Katz K, Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol. Merl 13, 663–670 (1983).
- Robinson D, Woerner MG, Alvir JM eta] Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psych. 56, 241–247 (1999).
- Gaebel W Pietzcker A. Multidimensional study of the outcome of schizophrenic patients 1 year after clinic discharge. Predictors and influence of neuroleptic treatment. Eur: Arch. Bych. Abutvl. Sri. 235, 45–52 (1985).
- Kane JM. Schizophrenia. N Engl. I Merl 334, 34–41 (1996).
- Davis JM. Maintenance therapy and the natural course of schizophrenia. J: Clin. Psych. 46, 18–21 (1985).
- Gitlin M, Nuechterlein K, Subotnik K et al Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset
- •• schizophrenia. Am. J. Psychiatry 158, 1835–1842 (2001).
- Misdrahi D, Llorca PM, Lancon C, Bayle FJ. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale 28,266–272 (2002).
- •Very current review of compliance and impact on treatment.
- Lieberman JA, Alvir JM, Koreen A et al Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology14, S13—S21 (1996).
- Davies LM, Drummond ME. Economics and schizophrenia: the real cost. BE J. Fiychiatry25, 18–21 (1994).
- Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 21 (3), 419–429 (1995).
- Babiker IE. Noncompliance in schizophrenia. PFchiatr Dev 4,329–337 (1986).
- Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. PharmacoEconomics 17,383–389 (2000).
- Kane JM, Aguglia E, Altamura AC etal Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference, Siena, Italy. Eur Neuropsychopharmacol 8,55–66 (1998).
- Walbum J, Gray R, Gournay K, Quraishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. BE J. Psychiatry 179,300–307 (2001).
- Janssen Pharmaceutica NV. Data on file. October 2001.
- Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. DITIF 47,741–773 (1994).
- Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. BE j Psychiatry 179, 290–299 (2001).
- Csernansky JG, Mahmoud R, Brenner R A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl. J. Med. 346, 16–22 (2002).
- ••Landmark study demonstrating the effectiveness of an atypical antipsychotic in relapse prevention.
- Love RC, Conley RR, Kelly DI, eta]. Rehospitalization rates with the atypical antipsychotics in the Maryland mental health system. Schizophr Res. 36,345 (1999).
- Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am. J. Health Syst. Pharm. 55, S17—S19 (1998).
- Turner M. Long-acting injectable risperidone for schizophrenia. Future Prescriber 3(1), (2002).
- Safarti Y, Olivier V, Bouhassira M. The use of new antipsychotics during treatment with schizoprenia — a European enquiry. LEncephale 25,658–666 (1999).
- Lasser RA, Ramstack JM, Grandolfi GP, Mannaert E, D'Hoore P Long-acting risperidone (Risperdal Constall : manufacture using Medisorb® microsphere technology, pharmacokinetics, and injection-site assessments. Presented at the 16th Annual Convention of the American Psychiatric Nursing Association, Oct 3–9, TX, USA (2002).
- Richelson E, Souder T Binding of antipsychotic drugs to human brain receptors. Life Sci. 68,29–39 (2000).
- Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin—dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. PFchiatry55,5–12 (1994).
- Summary of Product Characteristics. Risperdal ConstaTm. Risperidone long-acting injection. Janssen-Cilag Ltd, NY, USA (2002).
- Eerdekens M, Fleischhacker WW, Xie Y etal. Long-term safety and efficacy of Risperdal ConstaTM, the long-acting injection formulation of risperidone. Presented at the XXIII CINP Congress, June 23–27, Montreal, Canada (2002).
- Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J. Clin. PFchiatry62, 855–858 (2001).
- Kane J, Eerdekens M, Keith S, Lesem M, Karcher K, Lindenmayer J-P Efficacy and safety of a novel long-acting risperidone microspheres formulation. Presented at the 11th Biennial Winter Workshop on Schizophrenia, February 24—March 1, Davos, Switzerland (2002).
- Chue P, Eerdekens M, Augustyns I, Lachaux B, Mokan P, Eriksson L, Pretorius H, David A. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Presented at the 11th Biennial Winter Workshop on Schizophrenia, February 24—March 1, Davos, Switzerland (2002).
- Chue P, Devos E, Duchesne I, Leal A, Mehnert A. One-year hospitalization rates in patients with schizophrenia during long-term treatment with long-acting risperidone. Presented at The 7th Annual Meeting of the International Society for Pharmacoeconomic and Outcomes Research, May 19–22, Arlington, VA, USA (2002).
- Llorca P-M, Devos E, Eerdekens M, Duchesne I, Leal A, Mehnert A. Rehospitalization rates with long-acting risperidone injection are lower than those reported for other antipsychotics. Presented at the XXIII CINP Congress, June 23— 27, Montreal, Canada (2002).
- Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am. J. Psychiatry 158,266–269 (2001).
- Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. A117. I Psychiatry 156,863–868 (1999).
- Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch. Gen. Psych. 36,1283–1294 (1979).
- Remington G, Devos E, Eerdekens M, Duchesne I, Leal A, Mehnert A. Treatment with long-acting risperidone injection reduces healthcare resource use. Presented at the XXHI CINP Congress, June 23–27, Montreal, Canada (2002).
- Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in revolving door schizophrenic patients. Clin. Psych. 57, 337–345 (1996).
- Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. j Gun. PTchopharmacol. 17,298–307 (1997).
- Nasrallah H, Duchesne I, Mehnert A, Janagap C. Long-acting risperidone improves quality of life. Presented at the XXIII CINP COINIE4 June 23-27, Montreal, Canada (2002).
- Freyberger HJ, Eerdekens M, Duchesne I, Mehnert A, Rabinowitz J. Patient satisfaction with their medication during long-term treatment with long-acting risperidone injection. Presented at the XXIII CINP Congress, June 23–27, Montreal, Canada (2002).
- Kelleher JP, Centorrino F, Albert J, Baldessarini RJ. Advances in atypical antipsychotics for the treatment of schizophrenia. CNS Drugs16, 249–261 (2002).
- Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. PFhiatr Serv. 49,196–201 (1998).
- Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta PFhiatr &and. 102,83–86 (2000).
- Schooler NR, Keith SJ, Severe JB etal Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch. Gen. Psych. 54,453–463 (1997).
- Gaebel W, Janner M, Frommann N etal. First verses multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr. Res. 53, 145–159 (2002).
- Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psych. 58, 538–546 (1997).
- Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol. Med. 33,83–89 (2003).
- •Interesting study illustrating physicians' perspectives to treatment.
- Peuskens J. Switching approach in the management of schizophrenia patients. Int. Clin. Psychopharmacol 15\(Suppl. 4), S15—S19 (2000).
- Hay J. Complications at site of injection of depot neuroleptics. Br M611. 12,421 (1995).
- Hogarty GE, Ulrich RE The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J. Psychiatr Res. 32,243–250 (1998).